BioSpace News Archive

Biovica, active in cancer monitoring, announces that the company has signed a commercial partnership with the European distributor TOROMEDICAL group for the commercialization of the DiviTumTKa test for clinical routine use in the Netherlands and Poland.

Burning Rock Biotech Limited, a company focused on the application of next generation sequencing technology in the field of precision oncology, reported financial results for the three months and the year ended December 31, 2022.

Allarity Therapeutics, Inc. announced updates to its ongoing phase 2 clinical programs evaluating IXEMPRA® and stenoparib as monotherapies.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced positive results from the company’s Phase 1 single ascending dose and multiple ascending dose clinical trial of VK2735.

WuXi Biologics (“WuXi Bio”) (2269.HK) congratulates its strategic partner Amicus Therapeutics (“Amicus”) (Nasdaq: FOLD) on receiving European Commission’s approval for Pombiliti™ (cipaglucosidase alfa), a long-term enzyme replacement therapy (ERT) used in combination with miglustat for adults with late-onset Pompe disease (LOPD).

Milestone Pharmaceuticals Inc. announced that it has entered into a $125 million strategic funding agreement with existing shareholder, RTW Investments, LP and certain of its affiliates.

Oncolytics Biotech ® Inc. will participate in the Novel Mechanisms with Important Readouts panel at Cantor Fitzgerald’s The Future of Oncology Virtual Symposium, which is taking place April 3-5, 2023.

Viking Therapeutics, Inc. today announced that it has initiated a Phase 1 clinical study to evaluate a novel oral formulation of the company’s dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist VK2735.

Switch Therapeutics today announced the appointments of Craig Blanchette, Ph.D., as Senior Vice President, Research and Michael Wolfe as Senior Vice President, Finance and Operations, effective immediately.

Silence Therapeutics plc today announced it will be acquiring back exclusive worldwide rights to two siRNA drug targets under the collaboration agreement with Mallinckrodt Pharmaceuticals.